MedEngine Oy, a company specialized in high-quality medical data science services, and BC Platforms AG, a world leader in genomic data management and analytics, today announce a major strategic alliance to create turnkey research solutions for the pharmaceutical and health sectors. The first-of-a-kind partnership brings together BC Platform’s global network of biobanks and MedEngine’s expertise in medical research.
MedEngine provides scientific research, medical communications, and medical advisory services to generate impactful clinical, health economic, and market insights for the pharmaceutical and health tech industries. MedEngine’s internationally recognized projects translate research findings beyond scientific publications into medical practices and activities. By collecting, analyzing, and applying medical data, MedEngine helps its customers design better clinical trials, demonstrate the value of a product to payers, provide tools for treatment optimization, and make better business decisions.
With over 20 years’ experience working in genomics and information technology, BC Platforms has built a global network of biobanks to provide harmonized genomic and clinical cohort data for pharmaceutical and medical research. The company’s high-performing software platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information.
The new strategic alliance will integrate MedEngine’s research and business knowledge with BC Platforms’ global pool of biobank data and analytics platform. This will strengthen the partner companies’ ability to offer turnkey projects – from study concepts to finalized publications, and all the way to implementation of the data to the benefit of patients.
“We are excited about our new strategic partnership with MedEngine,” says Tero Silvola, CEO of BC Platforms. “We have chosen MedEngine as our strategic partner in service development and production because of MedEngine’s research excellence and deep understanding of customer needs. Together we can develop solutions that help turn data into meaningful knowledge.”
“Both MedEngine and BC Platforms are striving towards strong global growth. Through this partnership we have a unique opportunity to offer top-quality research services that are based on massive datasets of genomic and clinical data from BC Platform’s global network of biobanks,” says Tero Ylisaukko-oja, CEO of MedEngine.
MedEngine Oy is a medical science agency built upon extensive academic expertise and years of experience in the pharmaceutical and health tech industries. The company’s core competences are Medical Data Science, Medical Affairs and Marketing services, as well as business strategies. MedEngine’s customers are the world’s leading pharmaceutical and health technology companies and innovative healthcare start-up companies. In 2017, MedEngine was the fastest growing company in Finland specializing in expert services for pharmaceutical industry and health tech companies.
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. The high performing genomic data management platform developed by BC Platforms enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company created and launched a global network of biobanks, known as BCRQUEST.COM, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than 5 million subjects consolidated from a global network of biobanks.
Founded in 1997 from an MIT Whitehead project spinoff, the company has a strong scientific heritage underpinned by 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in London, Boston, and Vancouver.